Articles tagged with Lentiviruses
Researchers developed a novel lentivirus-based gene therapy strategy in CD34+ hematopoietic progenitor cells, which showed therapeutic levels of expression of the anti-sickling beta globin protein. Cyclosporin improved transduction efficiency and preserved cell viability.
Researchers identified the integration site pattern of lentiviral gene therapies in patient cells, shedding light on treatment safety and efficacy. The study found that integration near nuclear pores is associated with improved safety and effectiveness, avoiding oncogene regions where earlier technologies failed.
A new therapy delivery method, using modified viruses engineered with fusogens Myomaker and Myomerger, shows promise as a treatment for Duchenne muscular dystrophy. The vector can deliver a vital gene needed for muscle function to cells, potentially providing a lifelong supply of the missing gene.
Developed by University of Seville researchers, the new methodology has a sensitivity of 100% and specificity of 87.5%. It can detect SARS-CoV-2 in saliva and synthetic viruses with minimal equipment and training.
Primate lentiviruses, such as HIV-1, overcome species barriers through viral infectivity factor (Vif) and APOBEC3 protein interactions. A study by the University of Tokyo found that gorilla APOBEC3G can restrict SIVcpz replication but a specific amino acid substitution in Vif can evade this restriction.
Researchers discovered that lentiviruses closely related to HIV have infected primates in Africa as far back as 16 million years. The TRIM5 protein, an antiviral gene, has evolved to protect host cells from infection and provides insight into the evolution of viruses.
Researchers found a retrovirus in the DNA of a gray mouse lemur, suggesting lentiviruses may have coevolved with primates for millions of years. This discovery could lead to new insights into why non-human primates don't get AIDS and potential treatments for humans.